Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
narazaciclib (HX301) / Traws Pharma
NCT06351644: ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma	Recruiting	1/2	36	US	ON 123300, NARAZACICLIB, Dexamethasone, Decadron	Adriana Rossi	Relapsed and/or Refractory Multiple Myeloma	06/28	06/28
NCT05705505: Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies	Recruiting	1/2	60	US	Narazaciclib, ON 123300, HX-301, Letrozole 2.5mg, Femara	Onconova Therapeutics, Inc.	Endometrioid Endometrial Cancer	01/26	02/26
NCT04739293: Study of ON 123300 in Patients With Advanced Cancer	Recruiting	1	36	US	ON123300, HX 301	Onconova Therapeutics, Inc.	Solid Tumors, Adult	10/24	10/24
NCT05731934: The Tolerability and Pharmacokinetics of HX301 Monolactate Capsules in Patients With Advanced Solid Tumors	Completed	1	20	RoW	HX301, HX301 Monolactate Capsules	Hangzhou Hanx Biopharmaceuticals, Ltd., Wuhan Hanxiong Bioscience, Ltd.	Advanced Solid Tumors	01/24	01/24